This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (6)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Osteoporosis  • Women's Health, Other  • Adverse Effects  • Diabetes Mellitus  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2007;297:1645.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A warning from the US Food and Drug Administration (FDA) has linked pioglitazone (Actos), a thiazolidinedione prescribed for the treatment of type 2 diabetes, with an increased rate of arm, hand, and lower leg fractures among women. The action comes less than a month after a similar warning about excess fractures in women taking rosiglitazone (Avandia), another drug in the same class. The increased risk did not appear in men.

While the drugs remain on the market and continue to be valuable tools in physicians' therapeutic armamentarium against type 2 diabetes, investigators are striving to determine the mechanism of these effects and which patients are at increased risk.

(Photo credit: Simon Fraser/http://www.sciencesource.com)

RECENT WARNINGS

Thiazolidinediones, which lower insulin resistance, are often prescribed when other medications have failed to reduce blood glucose levels in patients with type 2 diabetes. As with a variety of other drugs, adverse effects . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Considering Competing Risks . . . Not All Black and White
Cauley and Ensrud
Arch Intern Med 2008;168:793-795.
FULL TEXT  

Use of Thiazolidinediones and Fracture Risk
Meier et al.
Arch Intern Med 2008;168:820-825.
ABSTRACT | FULL TEXT